TG Therapeutics (NASDAQ:TGTX) Issues Earnings Results

TG Therapeutics (NASDAQ:TGTX) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19, Zacks reports. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same quarter last year, the company earned $0.02 earnings per share. The company’s quarterly revenue was up 92.7% on a year-over-year basis. TG Therapeutics updated its FY 2025 guidance to EPS.

TG Therapeutics Stock Up 0.5%

TG Therapeutics stock opened at $33.86 on Wednesday. TG Therapeutics has a twelve month low of $23.60 and a twelve month high of $46.48. The firm has a market capitalization of $5.37 billion, a P/E ratio of 91.51 and a beta of 1.97. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The stock’s fifty day simple moving average is $33.66 and its 200-day simple moving average is $34.75.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TGTX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in TG Therapeutics by 5.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after buying an additional 14,689 shares during the last quarter. Rafferty Asset Management LLC lifted its stake in shares of TG Therapeutics by 3.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 188,220 shares of the biopharmaceutical company’s stock worth $6,774,000 after acquiring an additional 6,359 shares during the period. California State Teachers Retirement System lifted its position in TG Therapeutics by 10.3% in the second quarter. California State Teachers Retirement System now owns 149,512 shares of the biopharmaceutical company’s stock valued at $5,381,000 after purchasing an additional 13,982 shares during the period. Man Group plc acquired a new position in TG Therapeutics during the second quarter worth $5,030,000. Finally, Corient Private Wealth LLC grew its stake in shares of TG Therapeutics by 98.2% during the 2nd quarter. Corient Private Wealth LLC now owns 80,704 shares of the biopharmaceutical company’s stock worth $2,905,000 after purchasing an additional 39,987 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday. HC Wainwright initiated coverage on TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective on the stock. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Finally, JPMorgan Chase & Co. upped their target price on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.